Pfizer (PFE) PT Set at $42.00 by Credit Suisse Group

Credit Suisse Group set a $42.00 price target on Pfizer (NYSE:PFE) in a report published on Monday. The firm currently has a hold rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently commented on PFE. Cantor Fitzgerald set a $45.00 price objective on Pfizer and gave the company a buy rating in a research report on Thursday, October 4th. Morgan Stanley set a $45.00 price objective on Pfizer and gave the company a buy rating in a research report on Wednesday, August 29th. Bank of America boosted their price objective on Pfizer from $42.00 to $43.00 and gave the company a buy rating in a research report on Wednesday, August 1st. Goldman Sachs Group restated a neutral rating and issued a $45.00 price objective on shares of Pfizer in a research report on Tuesday, October 30th. Finally, Independent Research set a $48.00 price objective on Pfizer and gave the company a neutral rating in a research report on Thursday, October 4th. Two analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have assigned a buy rating to the company’s stock. Pfizer currently has an average rating of Hold and an average target price of $43.27.

Shares of PFE stock opened at $45.51 on Monday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.15. The company has a market cap of $262.34 billion, a P/E ratio of 17.17, a P/E/G ratio of 2.20 and a beta of 0.88. Pfizer has a twelve month low of $33.20 and a twelve month high of $45.83.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.03. The company had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. Pfizer’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period last year, the business earned $0.67 earnings per share. As a group, equities analysts predict that Pfizer will post 3 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date is Thursday, November 8th. Pfizer’s dividend payout ratio is presently 51.32%.

In other news, major shareholder Pfizer Inc purchased 55,556 shares of the stock in a transaction dated Monday, October 15th. The shares were purchased at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the purchase, the insider now directly owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.06% of the company’s stock.

Several large investors have recently modified their holdings of PFE. Capital World Investors boosted its stake in shares of Pfizer by 124.8% in the third quarter. Capital World Investors now owns 85,032,960 shares of the biopharmaceutical company’s stock worth $3,747,403,000 after acquiring an additional 47,202,436 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Pfizer by 60.2% in the third quarter. AQR Capital Management LLC now owns 23,151,759 shares of the biopharmaceutical company’s stock worth $1,020,298,000 after acquiring an additional 8,701,301 shares during the last quarter. Charles Schwab Investment Advisory Inc. acquired a new stake in shares of Pfizer in the second quarter worth approximately $286,229,000. Dimensional Fund Advisors LP boosted its stake in shares of Pfizer by 15.0% in the second quarter. Dimensional Fund Advisors LP now owns 54,233,658 shares of the biopharmaceutical company’s stock worth $1,967,651,000 after acquiring an additional 7,059,171 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Pfizer by 1.5% in the third quarter. Vanguard Group Inc. now owns 441,792,969 shares of the biopharmaceutical company’s stock worth $19,469,816,000 after acquiring an additional 6,620,749 shares during the last quarter. 68.64% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Further Reading: How the Consumer Price Index (CPI) is calculated?

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply